Publication
SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation
| dc.contributor.author | Lopes, António Cabral | |
| dc.contributor.author | Lourenço, Olga | |
| dc.contributor.author | Morgado, Manuel Augusto Nunes Vicente Passos | |
| dc.date.accessioned | 2024-12-11T09:42:02Z | |
| dc.date.available | 2024-12-11T09:42:02Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Abstract Background: We aimed to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) in patients with type 2 diabetes mellitus (T2DM) in clinical practice. Research design and methods: A total of 340 patients were included. Data on age, gender, antidiabetic medications, and bioanalytical parameters were collected at baseline and one year later. Were analyzed estimated glomerular filtration rate (eGFR), blood sodium and potassium levels, blood pressure, weight, cardiovascular risk, and glycated hemoglobin (HbA1c). Results: Patients treated with SGLT2i exhibited a significant improvement in eGFR at the endpoint compared to baseline (p = 0.006). Both treatment groups experienced reductions in systolic blood pressure at the endpoint; especially patients treated with SGLT2i (p = 0.0002). GLP1RA treatment resulted in a statistically significant weight reduction from baseline to endpoint (p < 0.0001), with a higher percentage of patients achieving ≥ 5% weight loss compared to the non-GLP1RA group (33.6% vs. 19.8%). Both SGLT2i and GLP1RA treatments significantly reduced cardiovascular risk scores (p = 0.004 and p = 0.002, respectively). Additionally, both treatments were associated with a significant reduction in HbA1c levels at the endpoint (p = 0.010 and p = 0.002, respectively). Conclusions: Our findings suggest that SGLT2i and GLP1RA offer beneficial effects in patients with T2DM. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Lopes AC, Lourenço O, Morgado M. SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation. Expert Rev Clin Pharmacol. 2024 Nov;17(11):1081-1088. doi: 10.1080/17512433.2024.2421872 | pt_PT |
| dc.identifier.doi | 10.1080/17512433.2024.2421872 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.6/14947 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.subject | Cardiovascular risk | pt_PT |
| dc.subject | GLP1 RA | pt_PT |
| dc.subject | HbA1c | pt_PT |
| dc.subject | Obesity | pt_PT |
| dc.subject | Renal function | pt_PT |
| dc.subject | SGLT2i | pt_PT |
| dc.title | SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 1088 | pt_PT |
| oaire.citation.issue | 11 | pt_PT |
| oaire.citation.startPage | 1081 | pt_PT |
| oaire.citation.title | Expert Review of Clinical Pharmacology | pt_PT |
| oaire.citation.volume | 17 | pt_PT |
| person.familyName | Lourenço | |
| person.familyName | Nunes Vicente Passos Morgado | |
| person.givenName | Olga Maria Marques | |
| person.givenName | Manuel Augusto | |
| person.identifier | AAG-4910-2021 | |
| person.identifier.ciencia-id | 6618-1C4C-D1B7 | |
| person.identifier.ciencia-id | 7617-9FDC-2D9D | |
| person.identifier.orcid | 0000-0002-8401-5976 | |
| person.identifier.orcid | 0000-0003-2112-2835 | |
| person.identifier.scopus-author-id | 55955252600 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | c890c74a-abc1-4910-aa70-f0da7b4ad902 | |
| relation.isAuthorOfPublication | 7c614887-225f-44d4-b467-3cc34e44a98b | |
| relation.isAuthorOfPublication.latestForDiscovery | c890c74a-abc1-4910-aa70-f0da7b4ad902 |